Showing 4021-4030 of 4164 results for "".
- FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside Of the Hospital Settinghttps://modernod.com/news/fda-cautions-against-use-of-hydroxychloroquine-or-chloroquine-for-covid-19-outside-of-the-hospital-setting/2477649/In a safety communication posted on Friday, the FDA warned consumers against taking malaria drugs chloroquine and hydroxychloroquine to treat COVID-19 outside a hospital or formal clinical trial setting. The updated guidance comes after reports of serious heart rhythm problems in patients with CO
- Lancet Neurology Publishes Pivotal Phase 3 Data for Genentech’s Satralizumab for NMOSDhttps://modernod.com/news/lancet-neurology-publishes-pivotal-phase-3-data-for-genentechs-satralizumab-for-nmosd/2477640/Lancet Neurology published full pivotal phase 3 clinical data on investigational medicine satralizumab as a monotherapy for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease that is commonly misdiagnosed as multiple scler
- Nicox Provides Business Update and Financial Highlightshttps://modernod.com/news/nicox-provides-business-update-and-financial-highlights/2477608/Nicox SA provided Q1 2020 operational highlights, revenue and cash position for Nicox SA and its subsidiaries, as well as updating key expected milestones in 2020. Key Expected Upcoming Milestones NCX 470 Mont Blanc Phase 3 clinical trial: The
- GenSight Biologics Announces Positive Safety Review of PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/gensight-biologics-announces-positive-safety-review-of-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-treatment/2477583/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, GenSight’s novel product combining gene therapy and optogenetics for the treatment of retinitis pigmentosa (RP
- Aldeyra Therapeutics Announces Potential of ADX-629 to Treat COVID-19 Patientshttps://modernod.com/news/aldeyra-therapeutics-announces-potential-of-adx-629-to-treat-covid-19-patients/2477578/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, plans to facilitate the clinical testing of its drug candidate ADX-629 in patients with COVID-19-associated respiratory compromise. The company has requested a pre-investigational new drug m
- Ocular Therapeutix Provides Business Update and Response to COVID-19 Global Pandemichttps://modernod.com/news/ocular-therapeutix-provides-business-update-and-response-to-covid-19-global-pandemic/2477571/Ocular Therapeutix announced its response to the COVID-19 pandemic and related impact on Ocular Therapeutix’s business operations. “In the midst of the global COVID-19 pandemic, our first priority is for the safety and well-being of our employees, patients, clinical collaborators and custo
- Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDAhttps://modernod.com/news/nicox-outlines-plans-to-progress-ncx-4251-into-phase-2b-trial-following-positive-meeting-with-fda/2477548/Nicox SA announced that it has held a Type C meeting with the FDA in which the data from the recently completed Danube phase 2 clinical trial of NCX 4251 was reviewed and the next NCX 4251 trial designs were discussed. Given the positive Danube phase 2 trial results in reduction of the signs and
- Incyte, Novartis to Evaluate JAK Inhibitor Ruxolitinib for Severe COVID-19 Patientshttps://modernod.com/news/incyte-novartis-to-evaluate-jak-inhibitor-ruxolitinib-for-severe-covid-19-patients/2477527/Incyte and Novartis announced that the companies plan to initiate a phase 3 collaborative study to assess ruxolitinib plus standard-of-care, versus standard care alone, in patients suffering from COVID-19-associated cytokine storm. The clinical trial will be sponsored by Incyte in the US, where t
- Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of Inhaled Nitric Oxide Therapy for COVID-19https://modernod.com/news/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/2477506/Mallinckrodt and Novoteris announced that the Therapeutic Products Directorate of Health Canada has cleared the companies’ joint pilot clinical trial, entitled “Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung
- Chinese Official Claims Fujifilm’s Avigan “Clearly Effective” in Treating COVID-19https://modernod.com/news/chinese-official-claims-fujifilms-avigan-clearly-effective-in-treating-covid-19/2477411/Results of clinical studies conducted in China suggest that Fujifilm’s Avigan (favipiravir) may be effective at treating patients with COVID-19. Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, remarked “it